All In Biotech

NDA 208232 · Chiesi

Mycapssa

Octreotide Acetate · Oral · Somatostatin Analog

Orphan

Last checked: Nov 19, 2026Latest source record: Jul 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jun 26, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

283

74 Phase 3, 26 recruiting

FAERS reports

5,732

4,922 serious, 920 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 24, 2025.

MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide (‎ 1 ).

Mechanism: Octreotide exerts pharmacologic actions similar to the natural hormone somatostatin, but is a more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin-releasing hormone (GnRH), decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 26, 2020 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabelReview
1 products under this application
  • MYCAPSSA · OCTREOTIDE ACETATE EQ 20MG BASE · CAPSULE, DELAYED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Octreotide" as an intervention, any sponsor and status, largest first.

All 283 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use753
  • drug ineffective718
  • diarrhoea550
  • death393
  • nausea373
  • fatigue325
  • malignant neoplasm progression253
  • abdominal pain232
  • vomiting219
  • weight decreased187
  • dyspnoea186
  • drug ineffective for unapproved indication185

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
200523
20065
20073
20082
200910
20109
201116
201270
2013105
2014143
2015192
2016225
2017343
2018380
2019347
2020333
2021572
2022630
2023600
2024542
2025682
2026494

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mycapssa (Octreotide Acetate)

2024 spending

$9.6M

Beneficiaries

128

1,051 claims

Per beneficiary

$75,110

$116.04 per unit

View as table
YearSpending
2020$364,153
2021$4,147,458
2022$4,544,439
2023$5,083,471
2024$9,614,038

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,135 on PubMed

Sponsor: Chiesi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.